Skip to main
CING
CING logo

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc, a clinical-stage biopharmaceutical company, operates within a growing market, with total ADHD medication sales in the U.S. expanding approximately 8% annually, reaching around $18 billion in 2020. The company’s proprietary precision timed-release drug delivery platform shows promise, as evidenced by positive topline results from its CTx-1301 trial, indicating a favorable effect on subjects compared to placebo. These developments suggest significant upside potential for Cingulate's stock, positioning the company to capitalize on robust market demand while mitigating associated risks through innovative product offerings.

Bears say

Cingulate Inc reported a net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which exceeded both the company's estimates of $(0.90) and the consensus estimate of $(0.87), highlighting a worse-than-expected financial performance. The company faces multiple significant risks that could impede its growth, including liquidity challenges, potential failures in demonstrating the safety and efficacy of its product candidates during clinical trials, and hurdles in obtaining necessary regulatory approvals. Additionally, competitive pressures and varying investor sentiment towards the biotech sector further complicate Cingulate's ability to capitalize on its proprietary drug delivery platform and achieve commercial success.

Cingulate (CING) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.